Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMJ6P9U)

Drug Name
T-226296 Drug Info
Synonyms
N-[6-(Dimethylaminomethyl)-5,6,7,8-tetrahydronaphthalen-2-yl]-4-(4-fluorophenyl)benzamide; T 226296; CHEMBL178707; 331758-35-1; 4'-Fluoro-N-[6-[(N,N-dimethylamino)methyl]-5,6,7,8-tetrahydro-2-naphthalenyl][1,1'-biphenyl]-4-carboxamide; 4'-Fluoro-N-[6-[(N,N-dimethylamino)methyl]-5,6,7,8-tetrahydro-2-naphthalenyl)[1,1'-biphenyl]-4-carboxamide; PDSP1_000981; LS-44229; LS-193063; SCHEMBL5582818; GTPL1314; GXAQELJVODWLDD-UHFFFAOYSA-N; BDBM50150715; PDSP2_000965; KB-80782; T226296; 102690-EP2272841A1; 102690-EP2301936A1; N-[6-(dimethylaminomethyl)-5,6,7,8-tetrahydronaphthalen-2-yl]-4-(4-fluorophenyl)benzamide; LS-193063; S-20951
Indication
Disease Entry ICD 11 Status REF
Obesity 5B81 Preclinical [1]
Atrial fibrillation BC81.3 Investigative [2]
Cross-matching ID
PubChem CID
9865843
TTD Drug ID
DMJ6P9U

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Patented Agent(s)
Approved Drug(s)
Discontinued Drug(s)
Investigative Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Melanin-concentrating hormone receptor 1 (MCHR1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
BMS-830216 DMCW71N Obesity 5B81 Phase 1 [4]
AZD1979 DMQ1OX4 Obesity 5B81 Phase 1 [5]
PMID25522065-Compound-27 DMXN4KB N. A. N. A. Patented [6]
PMID25522065-Compound-29 DMBNAK9 N. A. N. A. Patented [6]
PMID25522065-Compound-34 DMZDIRQ N. A. N. A. Patented [6]
PMID25522065-Compound-39 DM5YMQH N. A. N. A. Patented [6]
PMID25522065-Compound-40 DMCIQ01 N. A. N. A. Patented [6]
PMID25522065-Compound-11 DM410Z6 N. A. N. A. Patented [6]
PMID25522065-Compound-50 DMBWA0V N. A. N. A. Patented [6]
PMID25522065-Compound-12 DMVKO9C N. A. N. A. Patented [6]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Voltage-gated potassium channel Kv1.5 (KCNA5)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Dronedarone DMA8FS5 Angina pectoris BA40 Approved [2]
BMS-919373 DMN28WK Atrial fibrillation BC81.3 Phase 2 [7]
IQB-9302 DMET0H4 Pain MG30-MG3Z Phase 1 [8]
XEN-D0103 DMR0U4V Atrial fibrillation BC81.3 Phase 1 [9]
BMS-394136 DMGDJQR Arrhythmia BC9Z Phase 1 [10]
XEN-D0101 DMU0V45 Atrial fibrillation BC81.3 Phase 1 [11]
Zatebradine DMNYKOT Angina pectoris BA40 Terminated [12]
[14C]TEA DM6SFYH Discovery agent N.A. Investigative [13]
4-(4-phenoxybutoxy)-7H-furo[3,2-g]chromen-7-one DMKMH5L Discovery agent N.A. Investigative [14]
clofilium DMQ37OP Discovery agent N.A. Investigative [15]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Melanin-concentrating hormone receptor 1 (MCHR1) TTX4RTB MCHR1_HUMAN Antagonist [3]
Voltage-gated potassium channel Kv1.5 (KCNA5) TTW0CMT KCNA5_HUMAN Blocker [2]

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 1314).
2 New antiarrhythmic agents for atrial fibrillation and atrial flutter. Expert Opin Emerg Drugs. 2005 May;10(2):311-22.
3 Emerging drugs for obesity: linking novel biological mechanisms to pharmaceutical pipelines. Expert Opin Emerg Drugs. 2005 Aug;10(3):643-60.
4 2011 Pipeline of Bristol-Myers Squibb.
5 Phase I clinical trial of AZD1979 for treating obesity. AstraZeneca plc
6 Novel MCH1 receptor antagonists: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):193-207.
7 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800035504)
8 Stereoselective effects of the enantiomers of a new local anaesthetic, IQB-9302, on a human cardiac potassium channel (Kv1.5). Br J Pharmacol. 2001 Jan;132(2):385-92.
9 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 542).
10 Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
11 Human electrophysiological and pharmacological properties of XEN-D0101: a novel atrial-selective Kv1.5/IKur inhibitor. J Cardiovasc Pharmacol. 2013 May;61(5):408-15.
12 DOI: 10.1161/01.CIR.94.3.562
13 Pharmacological characterization of five cloned voltage-gated K+ channels, types Kv1.1, 1.2, 1.3, 1.5, and 3.1, stably expressed in mammalian cell lines. Mol Pharmacol. 1994 Jun;45(6):1227-34.
14 Substituted N-{3-[(1,1-dioxido-1,2-benzothiazol-3-yl)(phenyl)amino]propyl}benzamide analogs as potent Kv1.3 ion channel blockers. Part 2. Bioorg Med Chem Lett. 2010 Dec 1;20(23):6989-92.
15 Mechanism of clofilium block of the human Kv1.5 delayed rectifier potassium channel. Mol Pharmacol. 1995 Jan;47(1):198-205.